Profil
Dr. Speck is a distinguished professor and researcher in the field of cancer at Dartmouth Medical School and holds the James J.
Carroll Chair in Oncology.
Widely published and a recipient of numerous honors and grants, Dr. Speck received her B.A.
degree from Western Maryland College (now McDaniel College) in 1977, and her Ph.D.
in immunology from Northwestern University in 1982.
She trained as a postdoctoral fellow at the Center for Cancer Research and the Whitehead Institute at the Massachusetts Institute of Technology.
Dr. Speck moved to Dartmouth Medical School in 1989 as an Assistant Professor.
She is currently a Professor of Biochemistry, the Associate Director for Basic Science at the Norris Cotton Cancer Center at Dartmouth and holds the prestigious James J.
Carroll Chair in Oncology.
Anciens postes connus de Nancy A. Speck
| Sociétés | Poste | Fin |
|---|---|---|
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Directeur/Membre du Conseil | 08/09/2008 |
Formation de Nancy A. Speck
| McDaniel College | Undergraduate Degree |
| Northwestern University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Viragen, Inc.
Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Health Technology |
